Microparticle‐Enabled Local Sustained Delivery of Paroxetine for Osteoarthritis Treatment
Open Access
- 16 November 2026
- journal article
- Published by Wiley in Advanced Healthcare Materials
Abstract
Osteoarthritis (OA) is a prevalent joint disease characterized by irreversible cartilage degradation, chronic pain, and reduced quality of life. Current treatments, including nonsteroidal anti‐inflammatory drugs (NSAIDs) and corticosteroids, are largely palliative, ineffective for some patients, and associated with adverse effects. We have shown that paroxetine (Px), an FDA‐approved antidepressant, has potential as a disease‐modifying OA drug by inhibiting the G protein‐coupled receptor kinase 2 (GRK2). Elevated GRK2 activity drives inflammation, extracellular matrix degradation and cartilage damage in OA. By inhibiting GRK2, Px suppresses cartilage degeneration, enhances chondrocyte anabolic activity, and reduces inflammation in the OA joint. In this study, we develop a local, slow‐release drug delivery system that harnesses the therapeutic benefits of Px for OA treatment via microfluidic‐assisted encapsulation in size‐controlled poly(lactic‐co‐glycolic acid) (PLGA) microparticles (MP). In vitro studies show that the drug release profile is controlled by tuning the MP fabrication parameters. Efficacy testing shows that Px‐eluting PLGA microparticles (MP‐Px) decrease fibroblast cell migration and proliferation in vitro. In vivo, the intra‐articular implantation of MP‐Px in the clinically relevant destabilization of medial meniscus mouse OA model decreases chondrocyte apoptosis and has some anti‐inflammatory effects in the acute phase of OA. Safranin O staining indicates mild staining loss in MP‐treated groups, warranting further assessment of cartilage‐matrix safety with long‐term use. Importantly, serum Px levels remain low following MP‐Px treatment compared with intraperitoneally administered Px (IP‐Px). To the best of our knowledge, this biomaterial provides the first local intra‐articular delivery of Px. These short‐term findings in mice support further preclinical evaluation of MP‐Px, including its effects on the cartilage matrix and long‐term efficacy.This publication has 58 references indexed in Scilit:
- Macrophage Membrane‐Biomimetic Multi‐Layered Nanoparticles Targeting Synovial Angiogenesis for Osteoarthritis TherapyAdvanced Healthcare Materials, 2024
- Controlled Release of Ceria and Ferric Oxide Nanoparticles via Collagen Hydrogel for Enhanced Osteoarthritis TherapyAdvanced Healthcare Materials, 2024
- Injectable porous microspheres for articular cartilage regeneration through in situ stem cell recruitment and macrophage polarizationActa Biomaterialia, 2024
- Injectable microspheres adhering to the cartilage matrix promote rapid reconstruction of partial-thickness cartilage defectsActa Biomaterialia, 2024
- Nanoenabled Immunomodulatory Scaffolds for Cartilage Tissue EngineeringAdvanced Functional Materials, 2024
- Stem Cells Expansion Vector via Bioadhesive Porous Microspheres for Accelerating Articular Cartilage RegenerationAdvanced Healthcare Materials, 2023
- Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine‐Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic NanoparticlesAdvanced Science, 2023
- Preparation of Monodisperse Biodegradable Polymer Microparticles Using a Microfluidic Flow‐Focusing Device for Controlled Drug DeliverySmall, 2009
- Inhibition of β‐catenin signaling in articular chondrocytes results in articular cartilage destructionArthritis & Rheumatism, 2008
- Utilizing acid pretreatment and electrospinning to improve biocompatibility of poly(glycolic acid) for tissue engineeringJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2004